Status:
COMPLETED
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism
Lead Sponsor:
Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Collaborating Sponsors:
Department of Health
Conditions:
Schizophrenia
Extrapyramidal Syndrome
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications. We compare the incidence of using anticholiner...
Detailed Description
Objective: First generation antipsychotics frequently induced extrapyramidal side effects (EPS). Second generation antipsychotics were the choices for EPS intolerant schizophrenic patients. But which ...
Eligibility Criteria
Inclusion
- Age of 18-65 y/o;
- Female patients did not have pregnancy plans and must agree to use reliable pregnancy prevention methods if during childbearing age;
- Meet schizophrenia criteria of DSM-IV;
- Fulfill DSM-IV neuroleptic-induced acute dystonia or parkinsonism research criteria, the severity of acute dystonia or parkinsonism was greater than moderate degree (\>4) assessed by global impression of Extrapyramidal System Rating Scale (item 43 and 44 of ESRS);
- Patients or legal responsible people agree to join study and sign informed consent
Exclusion
- Had other axis I diagnosis of DSM-IV;
- Unstable major systemic diseases;
- Had neurological disorder influenced to EPS assessment;
- Substance abuse or dependence other then coffee or tobacco within 6 months before study
Key Trial Info
Start Date :
July 1 2000
Trial Type :
INTERVENTIONAL
End Date :
July 1 2003
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00331825
Start Date
July 1 2000
End Date
July 1 2003
Last Update
May 31 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taoyuan Mental Hospital
Taoyuan District, Taiwan, 330